Written by Jianping Liu, Xun Li and the CAM-Cancer Consortium.
Updated February 13, 2014

Green tea (Camellia sinensis)

What is it?

Scientific names 

Green tea is derived from Camellia sinensis, an evergreen shrub of the Theaceae family, which grows mainly in parts of Asia, the Middle East and Africa. It comes from the same plant as black tea but it is produced in a non-fermenting process thus is believed to be the strongest tea with the least loss of herbal elements. According to the fermentation degree and plants sources, there are classifications as green tea, white tea, yellow tea, black tea and dark tea. With increasing fermentation, the number of bioactive elements decreases.


Green tea contains antioxidants. The main active ingredients identified in green tea include polyphenolic compounds such as epicatechin (EC), epicatechin-3-gallate (ECG), epigallocatechin (EGC), and epigallocatechin-3-gallate (EGCG), which are thought to be responsible for their anti-carcinogenic and anti-mutagenic activity. Other polyphenols in green tea include flavanols and their glycosides and depsides such as cholorogenic acid, quinic acids, carotenoids, trigalloylglucose, lignin, protein, chlorophyll, minerals (depending on the soil content, aluminum and manganese), caffeine, and very small amount of methylxanthines. 

Application and dosage 

Green tea can be consumed as a brewed beverage or as dietary supplements in form of liquids, capsules, or tablets containing green tea extract. Commercial products, or green tea for medicinal use, are provided by tea manufacturers or different pharmaceutical herbal medicine companies. Water for green tea should be around 80 to 85 °C; the higher the quality of the leaves, the lower the temperature; high-quality green teas can have new water added as many as five times. Currently, there is no established recommended dose for green tea extract. For cancer prevention, studies have examined the effects of habitually drinking between one to ten cups per day, although these findings require confirmation. 


Green tea consumption began in China with legendary origins of more than 4,000 years ago. A legend suggests it was an Emperor called Shen Nung who accidentally discovered tea. Then green tea has an origin linked to the highest tier of Chinese society, which made it expensive and only accessible to the rich. It was not until the 14th century that green tea become widespread throughout China. It has been used for its taste and medicinal qualities in most of Asia. In the 16th century, green tea was introduced to Europe and the USA.1 

The Kissa Yojoki (Book of Tea), written by Zen priest Eisai in 1191, describes how drinking green tea can have a positive effect on the five vital organs and discusses tea's medicinal qualities.2 

Claims of efficacy/alleged indications 

A variety of health benefits have been suggested including cancer prevention, reduced risk for cardiovascular disease, increased bone density, fat loss promotion and protection against neurodegenerative disease. 

Mechanism of action 

Human studies on the pharmacokinetics of green tea polyphenols have been conducted. Polyphenols from green tea have been shown to be powerful antioxidants with anticarcinogenic properties. EGCG, the most abundant and biologically active polyphenol in green tea, induces apoptosis and suppresses proliferation of cancer cells by modulating multiple signal transduction pathways. EGCG can also covalently bind to cysteine residues in proteins through autoxidation and subsequently modulate protein function.3 Studies have shown that tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells. 

Prevalence of use 

Tea is the most popular beverage next to water around the world, and green tea accounts for 20% of tea consumption. It is particularly popular in China, Japan, and other South-East Asian countries. 

Legal issues 

Green tea is sold as beverage or dietary supplement. It therefore does not need to be approved by the FDA or EMA (European Medicines Agency), but no medicinal claims associated with green tea can be made. 

Cost and expenditure 

The cost of green tea differs substantially due to variable growing conditions, horticulture, production processing and harvesting time. Therefore, on the Internet in China, prices for green tea generally range from 2.67 Euros/3.63 USD per 500g to 284.82 Euros/388.22 USD per 500g in bulk. The price of green tea in the USA and Europe is about 12.46 Euros/17 USD per 500 mg 100 caps.

Citation Jianping Liu, Xun Li , CAM-Cancer Consortium. Green tea (Camellia sinensis) [online document]. http://ws.cam-cancer.org/The-Summaries/Herbal-products/Green-tea-Camellia-sinensis. February 13, 2014.


  1. History of green tea [Website], accessed 28.12.13
  2. Green tea. Retrieved Feb. 25, 2012, from Wikipedia [Website], accessed 28.12.13
  3. Tanaka T, Ishii T, Mizuno D, et al. (-)-Epigallocatechin-3-gallate suppresses growth of AZ521 human gastric cancer cells by targeting the DEAD-box RNA helicase p68. Free Radical Biology and Medicine 2011, 50(10):1324-1335.
  4. Yuan JM, Sun C, Butler LM. Tea and cancer prevention: epidemiological studies. Pharmarcology research 2011, 64(2):123-135.
  5. Boehm K, Borrelli F, Ernst E, Habacher G, Hung SK, Milazzo S, Horneber M. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD005004. DOI:10.1002/14651858.CD005004.pub2.
  6. Sturgeon JL, Williams M, van Servellen G. Efficacy of green tea in the prevention of cancers. Nurs Health Sci. 2009 Dec;11(4):436-46. doi: 10.1111/j.1442-2018.2009.00476.x.
  7. Liu J, Xing J, Fei Y. Green tea (Camellia sinensis) and cancer prevention: a systematic review of randomized trials and epidemiological studies. Chin Med. 2008 Oct 22;3:12.
  8. Tang N, Wu Y, Zhou B, Wang B, Yu R. Green tea, black tea consumption and risk of lung cancer: a meta-analysis. Lung Cancer. 2009; 65: 274-83.
  9. Fritz H, Seely D, Kennedy DA, Fernandes R, Cooley K, Fergusson D. Green tea and lung cancer: a systematic review. Integrative cancer therapies. 2013;12(1):7-24. Epub 2012/04/26.
  10. Wang Y, Yu X, Wu Y, Zhang D. Coffee and tea consumption and risk of lung cancer: a dose-response analysis of observational studies. Lung cancer (Amsterdam, Netherlands). 2012;78(2):169-70. Epub 2012/09/12.
  11. Zheng P, Zheng HM, Deng XM, Zhang YD. Green tea consumption and risk of esophageal cancer: a meta-analysis of epidemiologic studies. BMC gastroenterology. 2012;12:165.
  12. Sang LX, Chang B, Li XH, Jiang M. Green tea consumption and risk of esophageal cancer: a meta-analysis of published epidemiological studies. Nutrition and cancer. 2013;65(6):802-12. Epub 2013/08/06.
  13. Zheng JS, Yang J, Fu YQ, Huang T, Huang YJ, Li D. Effects of green tea, black tea, and coffee consumption on the risk of esophageal cancer: a systematic review and meta-analysis of observational studies. Nutrition and cancer. 2013;65(1):1-16. Epub 2013/02/02.
  14. Hou IC, Amarnani S, Chong MT, Bishayee A. Green tea and the risk of gastric cancer: Epidemiological evidence. World journal of gastroenterology : WJG. 2013;19(24):3713-22. Epub 2013/07/11.
  15. Kang H., Rha SY, Oh KW, Nam CM. Green tea consumption and stomach cancer risk: a meta-analysis. Epidemiology and Health 2010; 32:e2010001.
  16. Myung SK, Bae WK, Oh SM, Kim Y, Ju W, Sung J, Lee YJ, Ko JA, Song JI, Choi HJ. Green tea consumption and risk of stomach cancer: a meta-analysis of epidemiologic studies. Int J Cancer 2009; 124:670-7.
  17. Sasazuki S, Tamakoshi A, Matsuo K, Ito H, Wakai K, Nagata C, et al. Green tea consumption and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Japanese journal of clinical oncology. 2012;42(4):335-46. Epub 2012/03/01.
  18. Sing MF, Yang WS, Gao S, ect. Epidemiological studies of the association between tea drinking and primary liver cancer: a meta-analysis. European Journal of Cancer Prevention. 2011, 20(3):157-165.
  19. Sun CL, Yuan JM, Koh WP, Yu MC. Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 2006; 27:1301-9.
  20. Wang XJ, Zeng XT, Duan XL, Zeng HC, Shen R, Zhou P. Association between green tea and colorectal cancer risk: a meta-analysis of 13 case-control studies. Asian Pacific journal of cancer prevention : APJCP. 2012;13(7):3123-7.
  21. Wang ZH, Gao QY, Fang JY. Green tea and incidence of colorectal cancer: evidence from prospective cohort studies. Nutrition and cancer. 2012;64(8):1143-52. Epub 2012/11/21.
  22. Wang X, Lin YW, Wang S, Wu J, Mao QQ, Zheng XY, et al. A meta-analysis of tea consumption and the risk of bladder cancer. Urologia internationalis. 2013;90(1):10-6. Epub 2012/10/12.
  23. Wu S, Li F, Huang X, Hua Q, Huang T, Liu Z, Liu Z, Zhang Z, Liao C, Chen Y, Shi Y, Zeng R, Feng M, Zhong X,Long Z, Tan W, Zhang X. The association of tea consumption with bladder cancer risk: a meta-analysis. Asia Pac J Clin Nutr. 2013;22(1):128-37. doi: 10.6133/apjcn.2013.22.1.15.
  24. Qin J, Xie B, Mao Q, Kong D, Lin Y, Zheng X. Tea consumption and risk of bladder cancer: a meta-analysis. World J Surg Oncol. 2012 Aug 25;10:172. doi: 10.1186/1477-7819-10-172.
  25. Zheng J, Yang B, Huang T, Yu Y, Yang J, Li D. Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutrition and Cancer 2011; 63(5):663-672.
  26. Ogunleye AA, Xue F, Michels KB. Green tea consumption and breast cancer risk or recurrence: a meta-analysis. Breast Cancer Res Treat. 2010; 119:477-484.
  27. Wu Y, Zhang D, Kang S. Black tea, green tea and risk of breast cancer: an update. SpringerPlus. 2013;2(1):240. Epub 2013/06/12.
  28. Trudel D, Labbe DP, Bairati I, Fradet V, Bazinet L, Tetu B. Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies. Gynecologic oncology. 2012;126(3):491-8. Epub 2012/05/09.
  29. Butler LM, Wu AH. Green and black tea in relation to gynecologic cancers. Molecular Nutrition & Food Research 2011; 55(6):931-940.
  30. Nagle CM, Olsen CM, Bain CJ, etc. Tea consumption and risk of ovarian cancer. Cancer Causes and Control 2010; 21(9):1485-1491.
  31. Brown MD. Green tea (Camellia sinensis) extract and its possible role in the prevention of cancer. Altern Med Rev 1999;4:360-70.
  32. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. 2009 Apr;65(4):331-41. doi: 10.1007/s00228-008-0610-7. Epub 2009 Feb 6.
  33. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Cancer Res. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. 2006 Jan 15;66(2):1234-40.
  34. Nguyen MM, Ahmann FR, Nagle RB, Hsu CH, Tangrea JA, Parnes HL, Sokoloff MH, Gretzer MB, Chow HH. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev Res (Phila). 2012 Feb;5(2):290-8. doi: 10.1158/1940-6207.CAPR-11-0306. Epub 2011 Nov 1.
  35. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgenindependent metastatic prostate carcinoma. Cancer. 2003 Mar 15;97(6):1442-6.
  36. Thomas F, Holly JM, Persad R, ect. Green tea extract (epigallocatechin-3-gallate) reduces efficacy of radiotherapy on prostate cancer cells. Urology 2011; 78(2):421-475.
  37. Qiao J, Gu C, Shang W, ect. Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. Food and Chemical Toxicology 2011; 49(6):1410-1415.
  38. Bannerman B, Xu L, Jones M et al. Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol. 2011;68(5):1145-54.
  39. Golden EB, Lam PY, Kardosh A et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.Blood. 2009;113(23):5927-37.
  40. Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI, Low Dog T. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf. 2008;31(6):469-84.